Key result
MCP-1 boosts CD34-/CD14+ cell adhesion ~2.8-fold, promoting reendothelialization and limiting neointimal hyperplasia after arterial injury.
Answers are grounded in this paper and cite their sources.
Demonstrates that bone marrow monocyte lineage cells accelerate arterial reendothelialization in injured rats, indicating a novel cell therapy strategy for vascular repair.
Peripheral blood (PB)-derived CD14+ monocytes were shown to transdifferentiate into endothelial cell (EC) lineage cells and contribute to neovascularization. We investigated whether bone marrow (BM)- or PB-derived CD34-/CD14+ cells are involved in reendothelialization after carotid balloon injury. Although neither hematopoietic nor mesenchymal stem cells were included in human BM-derived CD34-/CD14+ monocyte lineage cells (BM-MLCs), they expressed EC-specific markers (Tie2, CD31, VE-cadherin, and endoglin) to an extent identical to mature ECs. When BM-MLCs were cultured with vascular endothelial growth factors, hematopoietic markers were drastically decreased and new EC-specific markers (Flk and CD34) were induced. BM-MLCs were intra-arterially transplanted into balloon-injured arteries of athymic nude rats. When BM-MLCs were activated by monocyte chemoattractant protein-1 (MCP-1) in vivo or in vitro, they adhered onto injured endothelium, differentiated into EC-like cells by losing hematopoietic markers, and inhibited neointimal hyperplasia. Ability to prevent neointimal hyperplasia was more efficient than that of BM-derived CD34+ cells. MCP-dependent adhesion was not observed in PB-derived CD34-/CD14+ monocytes. Regenerated endothelium exhibited a cobblestone appearance, blocked extravasation of dye, and induced NO-dependent vasorelaxation. Basal adhesive activities on HUVECs under laminar flow and beta1-integrin expression (basal and active forms) were significantly increased in BM-MLCs compared with PB-derived monocytes. MCP-1 markedly enhanced adhesive activity of BM-MLCs (2.8-fold) on HUVECs by activating beta1-integrin conformation. Thus, BM-MLCs can function as EC progenitors that are more potent than CD34+ cells and acquire the ability to adhere on injured endothelium in a MCP-1-dependent manner, leading to reendothelialization associated with inhibition of intimal hyperplasia. This will open a novel window to MCP-1-mediated biological actions and vascular regeneration strategies by cell therapy.
No takes yet. Share an insight, caveat, or question.
Fujiyama et al. (2003) studied Carotid balloon injury / endothelial injury. Human bone marrow-derived CD34-/CD14+ monocyte lineage cells (BM-MLCs) activated by MCP-1 vs. Peripheral blood-derived CD34-/CD14+ monocytes and bone marrow-derived CD34+ cells was evaluated on Reendothelialization, inhibition of neointimal hyperplasia, and adhesive activity on HUVECs (2.8-fold increase in adhesive activity). MCP-1 enhanced bone marrow-derived CD34-/CD14+ cell adhesion to HUVECs by 2.8-fold, promoting reendothelialization and inhibiting neointimal hyperplasia after arterial injury.
Synapse has enriched 10 related papers. Consider them for comparative context: